Helix BioPharma Corp.
HBPCF · OTC
7/31/2025 | 7/31/2024 | 7/31/2023 | 7/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 138.50 | 1.14 | 0.92 |
| FCF Yield | -8.27% | -4.09% | -3.00% | -4.39% |
| EV / EBITDA | -8.94 | -13,748.63 | -29.14 | -22.62 |
| Quality | ||||
| ROIC | -33.89% | 10.41% | 748.64% | -217.26% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.74 | 0.56 | 0.88 | 0.99 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 47.13% | 5.49% | 14.93% | 30.04% |
| Safety | ||||
| Net Debt / EBITDA | -0.05 | 117.18 | 0.13 | 0.12 |
| Interest Coverage | -542.55 | 0.00 | -451.86 | -363.17 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.07 |
| Cash Conversion Cycle | 0.00 | 0.00 | -13,841.92 | -13,231.25 |